For direct compression of arecoline hydrobromide in companion animal cestode control tablets, the API is typically milled and screened to a particle size distribution with D90 ≤ 150 µm and D50 45–75 µm before charging to the blender in jurisdictions where a current veterinary marketing authorization exists for the target species. Because the hydrobromide salt is hygroscopic, all dispensing and mixing operations are performed in a dehumidified suite maintained at ≤ 30% RH and 18–25°C product temperature; excursions above 40% RH during extended staging cause moisture pickup that increases punch sticking, die-wall friction, and weight variation on rotary presses. A staged blending sequence is used to avoid segregation of the low-dose API. The milled salt is first pre-blended with microcrystalline cellulose or dibasic calcium phosphate dihydrate at 1:5 to 1:10 in a bin blender at 10–20 rpm for 15–25 min. Croscarmellose sodium at 2–5% w/w is charged after the initial pre-blend, blended for 10–15 min, then magnesium stearate at 0.5–1.0% w/w is added and blended for 2–5 min. Compression is carried out on a rotary tablet press with B-tooling at main compression force 6–12 kN, producing tablets with hardness 5–8 kp and friability ≤ 0.8% determined by Ph. Eur. 2.9.7. Because of the narrow therapeutic index of arecoline, content uniformity is verified using USP <905> with acceptance value ≤ 15 and individual assay within 95–105% of label claim.

For tablets containing arecoline hydrobromide, moisture protection is extended into coating and packaging. A hypromellose-based film coat at 2–4% w/w weight gain is applied in a perforated pan coater with inlet air at 50–65°C and bed temperature 35–45°C; higher bed temperatures are considered only after forced degradation screening confirms no assay loss above 45°C. Packaging in PVC/PVDC/Alu blister with a silica gel desiccant canister maintains headspace relative humidity below 30% during shelf life, but seal integrity should be checked according to Ph. Eur. 3.2.2. The limit of arecaidine hydrolysis product is typically set at ≤ 1.0% by HPLC, with a stability protocol aligned to VICH GL3 zones I–IV. Avoid formulation with alkaline fillers or disintegrants that create a local pH above 6.5 in the tablet matrix, because the methyl ester moiety undergoes base-catalyzed hydrolysis. In-process control on the tablet press includes individual weight, thickness, hardness, and disintegration on samples taken every 15–30 min; weight variation is assessed by Ph. Eur. 2.9.5, and assay is performed on a composite of 20 tablets by reversed-phase HPLC. When a pharmacopoeial monograph is unavailable, the analytical procedure is validated according to VICH GL2 and the batch is released under 21 CFR Part 211 or equivalent veterinary GMP.

What Terminal Sterilization Options Remain Viable for Aqueous Arecoline Hydrobromide Solutions?

Aqueous injectable solutions are compounded at 0.1–1.0% w/v arecoline hydrobromide, adjusted to pH 3.5–5.0 with citrate or acetate buffer at 10–50 mM. The methyl ester substituent of arecoline is susceptible to base-catalyzed hydrolysis, so pH is maintained below 5.5 during dissolution, filtration, and storage; pH drift above 6.0 at 25°C can measurably increase arecaidine formation within hours. Dissolved oxygen is reduced by nitrogen sparging to ≤ 0.5 mg/L before aseptic filtration through 0.22 µm PVDF or PES membrane filters. Terminal steam sterilization at 121°C for 15 min is not routinely selected because the ester linkage is hydrolytically labile at elevated temperature; where sterility assurance level requires terminal treatment, an F0 of ≥ 8 min is evaluated only after forced degradation at 80°C for 24 h and 40°C/75% RH for 1 month demonstrates total degradation products ≤ 2.0%. Published data for this specific configuration is limited; therefore pre-validation studies are performed on a formulation-by-formulation basis.

The filled solution is held in Type I borosilicate glass vials or ampoules; amber glass is preferred if photostability screening shows a degradation increase above 0.2% after 1.2 million lux·h visible light and 200 W·h/m² UV exposure per ICH Q1B. Osmolality is adjusted to 270–320 mOsm/kg with sodium chloride, and pH is rechecked after terminal filtration. Aseptic filling is conducted in an ISO 14644-1 Class 5 cleanroom with Grade A unidirectional airflow. Release testing includes sterility per Ph. Eur. 2.6.1, bacterial endotoxins per Ph. Eur. 2.6.14, and subvisible particulate matter per Ph. Eur. 2.9.19. Multi-dose presentations must include an appropriate antimicrobial preservative validated by the efficacy test of Ph. Eur. 5.1.3; single-dose presentations without preservative are filled into ampoules or single-use vials. Incompatibility with cholinesterase inhibitors, organophosphate parasiticides, or alkaline injection vehicles should be documented in the manufacturing batch record because arecoline hydrobromide acts as a muscarinic agonist and concurrent exposure can amplify cholinergic effects.

Encapsulation of Low-Bulk-Density Hydrobromide Salts Requires Pre-Compaction

Arecoline hydrobromide as received often exhibits low bulk density (0.25–0.45 g/mL) and cohesive flow, making direct dosator filling unreliable. Pre-compaction by roller compactor with roll pressure 3–6 MPa and screen size 0.8–1.2 mm converts the API blend into free-flowing granules with Hausner ratio ≤ 1.25 and Carr index ≤ 20. A blend of 25–40% w/w API with microcrystalline cellulose and lactose monohydrate is lubricated with sodium stearyl fumarate at 0.25–0.75% w/w to reduce sticking in the compaction gap. Capsule filling on a dosator-type machine at 15,000–60,000 capsules/h uses size 1 to 3 hard gelatin capsules for fill weights from 100 to 300 mg. During filling, the environment is held at 35–45% RH and 20–25°C to prevent gelatin shell deformation and static charge buildup. Moisture content of the filled granulate is controlled at ≤ 0.5% LOD; higher moisture reduces flow and may induce cross-linking in gelatin shells during storage.

Capsule release testing includes disintegration per Ph. Eur. 2.9.1 in 0.1 M HCl at 37 ± 2°C with complete disintegration ≤ 15 min and content uniformity by USP <905>. A two-point dissolution test using 0.1 M HCl at 50 rpm paddle speed is typically validated according to VICH GL2, but published dissolution criteria for veterinary arecoline capsules are limited and acceptance ranges are derived from pilot bioequivalence or clinical field studies. Arecaidine formation in the capsule matrix is monitored by HPLC; an internal limit of ≤ 1.0% at release and ≤ 2.0% at shelf life is a conservative boundary when stability data are sparse. Hard gelatin capsules should be packaged in PVC/PVDC/Alu blisters with desiccant if distribution includes climate zones III–IV; moisture sorption isotherm screening at 25°C/60% RH and 40°C/75% RH is used to define barrier requirements.

In feed-mill production of oral powders containing arecoline hydrobromide, carrier selection is driven by electrostatic adhesion, segregation tendency, and the alkaline microclimate risk of mineral excipients. For a 0.5–5% w/w oral powder, the API is first adsorbed onto silica or spray-dried lactose monohydrate at 1:1 to 1:3 to blunt electrostatic charging. Geometric dilution at 1:1, 1:2, 1:4 ratios in a ribbon mixer or ploughshare mixer at 15–30 rpm for 10–20 min reduces localized high-concentration pockets. Homogeneity is evaluated by sampling 10–12 points; individual assay should be within 90–110% and relative standard deviation ≤ 5%. Because arecoline hydrobromide is hygroscopic, the final powder is packed in PET/Alu/LDPE pouches or multi-wall kraft bags with a LDPE liner, with release moisture ≤ 0.5% w/w and a desiccant sachet for high-humidity distribution zones.

Oral solutions are compounded at 0.05–0.2% w/v in purified water buffered to pH 3.5–5.0 with citrate buffer. Potassium sorbate at 0.1–0.2% w/w and sodium benzoate at 0.05–0.1% w/w are dissolved before API addition; the API is then added under light-protected conditions with mixing at 100–300 rpm for 20–40 min. The solution is filled into amber PET or HDPE bottles with calibrated dropper or drench gun closures. Dosing accuracy is verified by delivered volume, not by label fill volume, and the solution is tested for pH, assay, preservative content, and microbial limits per Ph. Eur. 5.1.4. Long-term use of oral solutions may require buffering capacity sufficient to resist pH drift above 5.5 after repeated container opening, because the ester linkage is unstable in weakly alkaline media.

When Granulation Solvent Polarity Is Adjusted for Hydrate Stability

When the granulation solvent is changed from pure water to a hydroalcoholic mixture, the hydrolysis rate of arecoline hydrobromide during high-shear wet granulation can be reduced without sacrificing granule growth. A solvent system of 70:30 to 90:10 v/v isopropanol or ethanol and purified water is commonly used with povidone K30 at 2–5% w/w as binder. Granulation is performed in a high-shear granulator with impeller speed 150–300 rpm and chopper 750–1500 rpm for 3–8 min wet massing. After wet massing, the granulate is dried in a fluid bed dryer with inlet air at 40–55°C until loss on drying is ≤ 1.0%; product temperature is held below 45°C because the ester linkage accelerates degradation at higher temperatures. The dried granulate is dry-sieved through 1.0 mm screen and the particle size distribution is controlled at D50 150–400 µm with fines below 100 µm limited to ≤ 25% w/w to ensure flow into sachets or tablet dies.

Residual solvent levels are tested by headspace GC according to USP <467>; isopropanol and ethanol are controlled as Class 3 solvents under ICH Q3C and are typically reported in the certificate of analysis for each batch. Granule stability is monitored for arecaidine at ≤ 1.0% release, and the granulate is stored in sealed containers at ≤ 25°C and ≤ 35% RH. The hydroalcoholic granulation route is particularly relevant when the final dosage form is a granule for oral administration, because it yields free-flowing material with better dosing uniformity than simple powder admixtures and lowers the water activity of the wet mass during processing. If sachet filling is used, fill weight variation is assessed by Ph. Eur. 2.9.5, and empty-sachet seal integrity is tested by dye penetration or vacuum leak method before release.

Premix Homogeneity and Segregation Risk in Mineral-Base Carriers

Segregation in mineral-base carriers is governed by particle size ratios, density differences, and electrostatic charge. For arecoline hydrobromide veterinary premix at 1–10% w/w, the API is dispersed onto a carrier such as calcium carbonate, corn starch, wheat middlings, or lactose monohydrate with carrier particle size 200–400 µm. Particle size mismatch is minimized by milling the API to D90 ≤ 150 µm; however, the hydrobromide salt may adhere strongly to metallic surfaces and mixer walls, requiring periodic scraper adjustment. Mixing in a double ribbon mixer or paddle mixer at 15–30 rpm for 10–20 min achieves a coefficient of variation ≤ 5% across 10 samples. Soybean oil or mineral oil at 0.5–1.5% w/w is sprayed onto the blend after dry mixing to reduce dusting and segregation during transfer; oil addition is followed by an additional 5–10 min mixing.

Alkaline carriers such as porous limestone or sodium bicarbonate should be avoided unless a pre-formulation slurry test confirms pH remains below 6.5; arecoline hydrobromide partitions into an alkaline microclimate where the methyl ester hydrolyzes to arecaidine. The final premix is filled into multi-wall paper bags with LDPE liner and stored at ≤ 25°C and ≤ 35% RH. Assay is performed by extraction with acidified methanol containing 0.1% phosphoric acid followed by reversed-phase HPLC; batch release includes identification, potency, and dispersion homogeneity. In feed-mill integration, the premix is incorporated at 0.1–1% w/w into final feed and mix time is validated by tracer studies; carryover contamination is controlled by sequencing and flush batches when the same line is used for non-medicated feed.